Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V. Hirayama, Cameron J. Turtle, Abigail Chutnik et al.|Blood Advances|2023Cited by 56
Development and validation of predictive models of early immune effector cell–associated hematotoxicityEmily C. Liang, Jordan Gauthier, Jennifer J. Huang et al.|Blood Advances|2024Cited by 11
T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case SeriesAya Albittar, Alexandre V. Hirayama, Alireza Torabi et al.|Transplantation and Cellular Therapy|2024Cited by 6
Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin LevelsJennifer J. Huang, Jordan Gauthier, Emily C. Liang et al.|Transplantation and Cellular Therapy|2024Cited by 3
Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.Jennifer J. Huang, Jordan Gauthier, Emily C. Liang et al.|Journal of Clinical Oncology|2024Cited by 2